Tesamorelin 10 mg

Research-grade lyophilized peptide powder supplied in a sterile glass vial. Tesamorelin, also known as TH9507, is a synthetic analogue of human Growth Hormone-Releasing Hormone (GHRH), investigated in controlled laboratory settings for its role in GH/IGF-1 axis modulation, visceral adiposity research, metabolic regulation, and lipodystrophy-related models.

Research Use Only

This product is intended strictly for laboratory and scientific investigation. Not for human consumption, therapeutic use, or veterinary application.

Specifications

Purity

99%+ (HPLC, third-party tested)

Form

Lyophilized peptide powder

Content

10 mg Tesamorelin per vial

Packaging

Sterile glass vial with secure closure

Storage

Store lyophilized at 2–8 °C in a dry, desiccated place, protected from light

Molecular Formula

C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular Weight

~5135.8 g·mol⁻¹

Sequence

(trans-3-hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂

Other Names

TH9507, Tesamorelin acetate

CAS Number

218949-48-5

Reconstitution

For diluting lyophilized peptide powders, use a sterile and suitable research solvent such as bacteriostatic water (BAC), which may help support handling stability and reduce contamination risk.

For convenient laboratory use, see Bacteriostatic Water – 10 ml.

Research Overview

Tesamorelin is a synthetic analogue of human Growth Hormone-Releasing Hormone (GHRH), comprising the full 44-amino acid sequence with an N-terminal trans-3-hexenoyl modification that improves stability and resistance to enzymatic degradation. In laboratory settings, it is investigated for its role in GH release, IGF-1 pathway signaling, visceral adipose tissue dynamics, lipodystrophy-like states, and broader metabolic and neuroendocrine regulation. No therapeutic or clinical claims are made or implied.

Primary Research Areas

GH/IGF-1 Axis & Pituitary Signaling

Experimental use in models evaluating how GHRH analogue stimulation influences pituitary growth hormone release, circulating IGF-1 levels, and downstream anabolic and metabolic signaling.

Visceral Adiposity & Lipodystrophy Models

Preclinical research focused on visceral fat accumulation, abnormal fat distribution, and associated metabolic changes in lipodystrophy-like experimental paradigms.

Metabolic Regulation & Glucose–Lipid Interaction

Research investigating relationships between GH/IGF-1 signaling, glucose handling, lipid metabolism, and insulin sensitivity across metabolic study models.

Body Composition & Tissue Remodeling

Used in studies examining lean mass, fat mass, and tissue remodeling to characterize the effects of chronic GHRH–GH–IGF-1 axis modulation on body composition.

Neuroendocrine & Cognitive Research

Investigated in experimental systems assessing hypothalamic–pituitary regulation, neuroendocrine feedback loops, and cognition-related endpoints in aging or metabolic-stress research.

Laboratory handling note:
Lyophilized peptides are commonly reconstituted using sterile research diluents such as bacteriostatic water (BAC).